Quanterix to Present at Goldman Sachs 47th Annual Global Healthcare Conference and Report Q2 2026 Financial Results
核心洞察
Quanterix CEO Everett Cunningham will deliver a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami on June 9, 2026, providing a strategic update on the company.
The company will report its second quarter 2026 financial results on August 10, 2026, followed by a conference call at 8:30 AM ET.
Quanterix's Simoa (搜索) technology enables ultra-sensitive biomarker detection, and the 2025 acquisition of Akoya Biosciences (搜索) added spatial biology capabilities with single-cell resolution.
Quanterix Corporation (搜索) (Nasdaq: QTRX), a company focused on accelerating biomarker breakthroughs from discovery to diagnostics, has announced two key upcoming events: participation in the Goldman Sachs 47th Annual Global Healthcare Conference and the scheduled release of its second quarter 2026 financial results.
Goldman Sachs Global Healthcare Conference Participation
Senior management from Quanterix will participate in the Goldman Sachs 47th Annual Global Healthcare Conference, taking place in Miami, Florida from June 8–10, 2026. Chief Executive Officer Everett Cunningham will engage in a fireside chat at 1:20 PM ET on Tuesday, June 9, during which he will provide an update on the company and its strategic priorities. The company is also scheduling one-on-one investor meetings at the event.
A live webcast of the presentation will be accessible from the Investor Relations section of the company's website at www.quanterix.com, with a replay available following the conference.
Second Quarter 2026 Financial Results
Quanterix also announced that it will host a conference call on Monday, August 10, 2026, at 8:30 AM ET, to discuss its second quarter 2026 financial results. The company will issue a press release regarding these results prior to the conference call on the same day, which will be posted on the Quanterix website.
The dial-in number for the conference call is Toll-Free (800) 715-9871 or (646) 307-1963, with conference ID 9896910. A live webcast will also be available from the Investors section of the Quanterix website, and an archived replay will remain accessible for one year.
Quanterix's Technology Platform and Strategic Position
Quanterix is a global leader in ultra-sensitive biomarker detection, with its proprietary Simoa (搜索) technology delivering industry-leading sensitivity that allows researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. The company's technology has been validated through approximately 6,500 peer-reviewed publications and nearly two decades of partnership with the scientific community.
In 2025, Quanterix acquired Akoya Biosciences (搜索), The Spatial Biology Company, adding multiplexed tissue imaging with single-cell resolution to its portfolio and bringing the total installed instrument base to 1,450. The combined entity now offers an integrated platform that connects biology across blood and tissue, advancing precision medicine from discovery to diagnostics. The company's spatial solutions, delivered through the Akoya acquisition, provide high-plex, quantitative protein analysis in tissue at single-cell resolution. Complemented by Accelerator Laboratory services, Quanterix provides researchers with tools and expertise to translate discovery into precision diagnostics.